Mineralocorticoid Receptor Antagonist in the Art of Managing HFpEF
You don’t have access to this content.
Mineralocorticoid Receptor Antagonist in the Art of Managing HFpEF
This webinar was held live on Wednesday 14th May 2025 at 07:00 am EDT / 12:00 pm BST / 13:00 CEST / 15:00 GST.
Organised by the International Society of Cardiovascular Pharmacotherapy (ISCP), this free, 1-hour session provided healthcare professionals with a comprehensive overview of the evolving role of mineralocorticoid receptor antagonists (MRAs) in managing heart failure with mid-range ejection fraction (HFmEF) and preserved ejection fraction (HFpEF).
Non-steroidal MRAs, such as finerenone, have garnered particular attention due to their more selective mechanism of action, which may offer advantages over traditional steroidal MRAs like spironolactone and eplerenone. Data from pivotal trials, including FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF, have provided compelling evidence that MRAs contribute to significant reductions in the combined endpoints of cardiovascular death and heart failure hospitalizations in patients with HFmEF and HFpEF.
The webinar highlighted the pathophysiology of mineralocorticoid receptor activation and its contribution to inflammation, fibrosis, and volume overload in heart failure. It also covered key clinical trials and meta-analyses supporting the expanded use of MRAs beyond HFrEF, practical considerations for selecting appropriate patients for MRA therapy, and future directions in MRA research and its integration into evolving heart failure treatment guidelines.
Participants engaged with international experts, including Dr. Vebiona Kartini Prima Putri (Indonesia) as moderator, and speakers Dr. Craig Beavers (USA), Dr. Bassam Atallah (UAE), and Dr. Lorenz Van der Linden (Belgium), who shared insights on applying MRAs in everyday practice.
This educational activity, supported by an unrestricted educational grant from Bayer, was free of charge if watched live. On-demand recordings are exclusive to ISCP members. For more information, please visit the ISCP webinar page.
Learning Objectives
- Explore the evolving role of mineralocorticoid receptor antagonists (MRAs) in managing HFpEF and HFmEF.
- Understand the mechanism of action and therapeutic potential of non-steroidal MRAs such as finerenone.
- Review key clinical trials including FIDELIO-DKD, FIGARO-DKD, and FINEARTS-HF and their implications for practice.
- Identify appropriate patient populations for MRA therapy and discuss practical considerations for implementation.
- Align treatment strategies with current guidelines and evidence to optimize outcomes in patients with HFpEF.

Dr Vebiona Kartini Prima Putri
Moderator
Dr Vebiona Kartini Prima Putri moderated the session from Indonesia, guiding discussions with clinical clarity and regional insight.

Dr Craig Beavers
Speaker
Joining from the USA, Dr Craig Beavers presented on integrating MRAs into real-world heart failure treatment practices.

Dr Bassam Atallah
Speaker
Dr Bassam Atallah brought perspectives from the UAE, focusing on patient selection and practical application of MRAs in HFpEF management.

Dr Lorenz Van der Linden
Speaker
From Belgium, Dr Lorenz Van der Linden examined trial data and future directions for non-steroidal MRAs in heart failure care.
Mineralocorticoid Receptor Antagonist in the Art of Managing HFpEF
Wednesday 14th May 2025 @ 1:00 pmDr Vebiona Kartini Prima Putri (Indonesia) – Moderator Dr Craig Beavers (USA) – Speaker Dr Bassam Atallah – Panelist Dr Lorenz Van der Linden – Panelist